Bioniche Presents E. coli O157:H7 Vaccine Data to International Congress of Medical Microbiology in Serbia

BELLEVILLE, ON, June 17 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, presented data regarding its E. coli O157:H7 cattle vaccine at the 6th Congress of Medical Microbiology - Mikromed 2008 in Belgrade, ...

New study highlights stigma and stress of living with HIV/AIDS in Serbia

Many people with HIV/AIDS in Serbia and Montenegro experience stigma, loneliness and ostracism, and can find it difficult to secure work and support themselves, according to new research findings. They also struggle to secure regular, continuous access to HIV/AIDS drug treatments even though, ...

Hard to Treat Diseases, Inc. (HTDS) Thai Registration Dossier

...y Yuan CEO of HTDS said (sic) "We welcome the expanded role of the medical team in Serbia. There has been a great synergy between the medical group in serbia and us here in China, right from day one. I have great admiration for the work they are doing which is simply amazing. It is our goal and target to se...

Hard To Treat Diseases (HTDS) Best Technological Innovation Award 2009

...in product, confirming its combative effective against glial scarring. HTDS Chief Scientist, Dr. Sanja Pekovic was elected as an expert to represent serbia in the COST (European Cooperation In The Field of Scientific And Technical Research) Action B30: Neural Regeneration and Plasticity. Meetings are sche...

Hard to Treat Diseases (HTDS) enters Guatemala market

... University of Toronto Canada. Andrea Zecevic is the company's Chief Project Scientist, R&D and the Chief Liaison Director between the China and serbia operating subsidiaries. For any corporate matters, readers should contact the company directly at corporate@htdsmedical.com " target="_new"> cor...

HARD TO TREAT DISEASES (HTDS) Influenca Vaccine (MEVAC-FLU) Enters Chilean Market

... University of Toronto Canada. Andrea Zecevic is the company's Chief Project Scientist, R&D and the Chief Liaison Director between the China and serbia operating subsidiaries. For any corporate matters, readers should contact the company directly at corporate@htdsmedical.com " target="_new"> corporat...

Hard To Treat Diseases (HTDS) - Large scale integrating project HEALTH 2009

... University of Toronto Canada. Andrea Zecevic is the company's Chief Project Scientist, R&D and the Chief Liaison Director between the China and serbia operating subsidiaries. For any corporate matters, readers should contact the company directly at corporate@htdsmedical.com " target="_new"> corporat...

Hard to Treat Diseases (HTDS) Releases experimental results in the treatment of (MS) Multiple Sclerosis

... University of Toronto Canada. Andrea Zecevic is the company's Chief Project Scientist, R&D and the Chief Liaison Director between the China and serbia operating subsidiaries. For any corporate matters, readers should contact the company directly at corporate@htdsmedical.com " target="_new"> corporat...

Hard To Treat Diseases (HTDS) To Name New CEO and Directors

...DS Chief Project Scientist and Director, R&D has been going over all the documents we provided and is receiving feedbacks from the doctors team in serbia and completing organizing and indexing all submissions. She has done an extraordinary job in putting the whole team together." Mr. Keith Roberts out...

Hard To Treat Diseases (HTDS) Recapitalization

...a Bio Chem merger. Consideration for Slavica is 300 million non-dilatable restricted shares to be distributed amongst all doctors involved in Belgrade serbia research. Key medical consultants and X ReNuYu management will receive stock options at a .03c strike price for up to 9% of the company common stock. ...

Serbia in Biological Technology

Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008

...e U.S., is evaluating MVA-BN(R)-HER2 treatment following first or second-line chemotherapy (including Herceptin(R)). In the second study, performed in serbia and Poland, MVA-BN(R)-HER2 is being evaluated following first or second-line chemotherapy or in combination with single-agent taxane chemotherapy. Bot...